Women harbouring a germline mutation in the BRCA1 and/or BRCA2 genes have an increased risk of breast and ovarian cancer.1 The most effective way to diminish this ovarian cancer risk is removing fallopian tubes and ovaries during risk‐reducing salpingo‐oophorectomy (RRSO), preferably around the age of 40 years.2, 3 However, salpingo‐oophorectomy at that age results in acute onset of premature menopause with several short‐ and long‐term health consequences.4, 5, 6. Here, BRCA2 is linked to ovarian carcinoma.